EFFECT OF HYPOXIA ON DNA SYNTHESIS AND C－MYC GENE EXPRESSION OF PULMONARY ARTERY SMOOTH MUSCLE CELLS

ＥＦＦＥＣＴＯＦＨＹＰＯＸＩＡＯＮＤＮＡＳＹＮＴＨＥＳＩＳＡＮＤＣ－ＭＹＣＧＥＮＥＥＸＰＲＥＳＳＩＯＮＯＦＰＵＬＭＯＮＡＲＹＡＲＴＥＲＹＳＭＯＯＴＨＭＵＳＣＬＥＣＥＬＬＳＬｕｏＬａｎ（罗兰）；ＬｉＳｈｉｑｉａｎｇ（李世强）ａｎｄＣａｉＹｉｎｇｎｉａｎ...     

SURGICAL TREATMENT OF HALLUX VALGLUS BY RECONSTRUCTION OF METATARSAL ARCH AND MODIFIED MCBRIDE OPERATION （40 CASES REPORT）

ＳＵＲＧＩＣＡＬＴＲＥＡＴＭＥＮＴＯＦＨＡＬＬＵＸＶＡＬＧＬＵＳＢＹＲＥＣＯＮＳＴＲＵＣＴＩＯＮＯＦＭＥＴＡＴＡＲＳＡＬＡＲＣＨＡＮＤＭＯＤＩＦＩＥＤＭＣＢＲＩＤＥＯＰＥＲＡＴＩＯＮ（４０ＣＡＳＥＳＲＥＰＯＲＴ）ＷｅｎｇＸｉｓｈｅｎｇ（翁习生）；Ｈｅ...     

ANTITUMOR ACTIVITY OF IMMUNOCONJUGATES COMPOSED OF BOANMYCIN AND MONOCLONAL ANTIBODY

ＡＮＴＩＴＵＭＯＲＡＣＴＩＶＩＴＹＯＦＩＭＭＵＮＯＣＯＮＪＵＧＡＴＥＳＣＯＭＰＯＳＥＤＯＦＢＯＡＮＭＹＣＩＮＡＮＤＭＯＮＯＣＬＯＮＡＬＡＮＴＩＢＯＤＹ￥ＺｈｅｎＹｏｎｇｓｕ；（甄永苏）；ＰｅｎｇＺｅ（彭泽）；ＤｅｎｇＹｏｎｇｃｈｕａｎ；（邓甬川）Ｘｕ...     

A COMPARATIVE STUDY OF IMOVANE AND ESTAZOLAM TREATMENT ON SLEEP DISTURBANCES

ＡＣＯＭＰＡＲＡＴＩＶＥＳＴＵＤＹＯＦＩＭＯＶＡＮＥＡＮＤＥＳＴＡＺＯＬＡＭ　ＴＲＥＡＴＭＥＮＴＯＮＳＬＥＥＰＤＩＳＴＵＲＢＡＮＣＥＳＬｉＳｈｕｎｗｅｉ（李舜伟）ａｎｄＷａｎｇＣｈａｎｇｈｕａ（王长华）（ＤｅｐａｒｔｍｅｎｔｏｆＮｅｕｒｏｐｓｙｃｈｉ...     

BENEFICIAL EFFECT OF CHROMIUM-RIGH YEAST ON GLUCOSE METABOLISM OF DIABETES

ＢＥＮＥＦＩＣＩＡＬＥＦＦＥＣＴＯＦＣＨＲＯＭＩＵＭ一ＲＩＣＨＹＥＡＳＴＯＮＧＬＵＣＯＳＥＭＥＴＡＢＯＬＩＳＭＯＦＤＩＡＢＥＴＥＳＹｕＸｕｅｍｅｉ（于雪梅）（Ｄｅｐｔ．ｏｆＭｅｄｉｃｉｎｅ，ＴａｉｓｈａｎＭｅｄｉｃａｌＣｏｌｌｅｇｅ）ＢＥＮＥＦＩＣＩ...     

EVALUATION OF EFFICACY OF RECOMBINANT-IFN IN TREATMENT OF CHRONIC HEPATITIS C

ＥＶＡＬＵＡＴＩＯＮＯＦＥＦＦＩＣＡＣＹＯＦＲＥＣＯＭＢＩＮＡＮＴ－ＩＦＮＩＮＴＲＥＡＴＭＥＮＴＯＦＣＨＲＯＮＩＣＨＥＰＡＴＩＴＩＳＣｊｉｎｇｅｎｄｉ（金根娣）（ＣｌｉｎｉｃａｌＶｉｒａｌＲｅｓｅａｒｃｈＬａｂｏｒａｔｏｒｙ，ＲｕｉｊｉｎｇＨｏｓｐｉ...     

ABNORMAL CARDIOVASCULAR REFLEXES IN PATIENTS WITH ACHALASIA

ＡＢＮＯＲＭＡＬＣＡＲＤＩＯＶＡＳＣＵＬＡＲＲＥＦＬＥＸＥＳＩＮＰＡＴＩＥＮＴＳＷＩＴＨＡＣＨＡＬＡＳＩＡＧｅＦｅｎｇ（戈烽）；ＬｉＺｅｊｉａｎ（李泽坚）ａｎｄＫｅＭｅｉｙｕｎ（柯美云）（ＰＵＭＣＨｏｓｐｉｔａｌ，ＣＡＭＳ＆ＰＵＭＣ，Ｂｅｉｊｉｎｇ１...     

ROLE OF COLLAGEN METABOLISM CHANGES IN THE PATHOGENESIS OF PULMONARY HYPERTENSION IN RATS AND ITS REVERSIBILITY

ＲＯＬＥＯＦＣＯＬＬＡＧＥＮＭＥＴＡＢＯＬＩＳＭＣＨＡＮＧＥＳＩＮＴＨＥＰＡＴＨＯＧＥＮＥＳＩＳＯＦＰＵＬＭＯＮＡＲＹＨＹＰＥＲＴＥＮＳＩＯＮＩＮＲＡＴＳＡＮＤＩＴＳＲＥＶＥＲＳＩＢＩＬＩＴＹＳｕｎＲｅｎｙｕ（孙仁宇）；ＹａｎＹｉｚｈａｏ（严仪昭）；...     

CLINICAL APPLICATION OF EXPANDED POLYTETRAFLUOROETHYLENE PERICARDIAL MEMBRANE IN PEDIATRIC CARDIAC SURGERY

ＣＬＩＮＩＣＡＬＡＰＰＬＩＣＡＴＩＯＮＯＦＥＸＰＡＮＤＥＤＰＯＬＹＴＥＴＲＡＦＬＵＯＲＯＥＴＨＹＬＥＮＥＰＥＲＩＣＡＲＤＩＡＬＭＥＭＢＲＡＮＥＩＮＰＥＤＩＡＴＲＩＣ　ＣＡＲＤＩＡＣＳＵＲＧＥＲＹＷａｎｇＳｈｕｎｍｉｎ（王顺民），ＳｕＺｈａｏｋａｎｇ（...     

CONSTRUCTION AND APPLICATION OF HUMAN CHROMOSOMAL SPECIFIC DNA PROBE P

ＣＯＮＳＴＲＵＣＴＩＯＮＡＮＤＡＰＰＬＩＣＡＴＩＯＮＯＦＨＵＭＡＮＣＨＲＯＭＯＳＯＭＡＬＳＰＥＣＩＦＩＣＤＮＡＰＲＯＢＥＰＯＯＬＳＬｉＬｕｙｕｎ李麓芸Ｉｎ１９８３－１９８６，ｔｗｅｎｔｙ－ｆｏｕｒｈｕｍａｎｃｈｒｏｍｏｓｏｍａｌｔｙｐｅｓｗｅｒｅｃｏ...     

支气管扩张试验后哮喘患者痉挛气道的解痉时相研究

目的：研究哮喘患者痉挛气道的解痉时相线性规律,为哮喘患者的解痉治疗提供理论依据。方法：16例哮喘发作期患者和14例志愿者进行支气管扩张试验,雾化吸入沙丁胺醇后15 min、30 min、1 h、2 h及4 h各个时间点,分别记录FVC、FEV₁、PEF反映大气道功能,以及MMEF、V₅₀、V₂₅反映小气道功能。以志愿者为对照,观察哮喘患者大、小气道解痉时相的差异。建立哮喘患者肺功能指标拟合直线方程,比较拟合直线方程斜率,对哮喘患者大、小气道解痉时相对比分析。 结果：在2 h时哮喘患者痉挛的大气道已经达到完全解痉,FVC、FEV₁、PEF与对照组比较 差异无显著性。小气道解痉的时间明显滞后,在观察期内各个时间点,除V₅₀外,哮 喘患者的MMEF、V₂₅与对照组比较差异有显著性（P<0.05）。FVC、FEV₁、PEF 随时间变化曲线图的拟合直线方程斜率小于0的所占百分比较低;而MMEF、V₅₀、₂₅所占百分比较高（P<0.05）。 结论：哮喘患者痉挛的大、小气道解痉时相不同,大气道先解痉,而小气道解痉延迟。临床可针对大气道痉挛为主的患者选用长效或短效药物,而小气道痉挛为主的患者适于选择长效药物。     

The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation

The cardiovascular effects of equal doses (5 mg) of nebulised fenoterol, salbutamol and terbutaline were compared in 12 healthy individuals in a double-blind, placebo-controlled study. Measurements of heart rate, blood pressure, systolic time intervals, QTc interval and T-wave amplitude were made at baseline and at 15, 30, 45, 60 and 90 minutes after nebulisation. Fenoterol caused significantly greater chronotropic electrocardiographic and inotropic effects than either salbutamol or terbutaline. The peak effects after terbutaline occurred later than those after fenoterol or salbutamol.     

噻托溴铵联合福莫特罗与沙美特罗替卡松治疗稳定期慢性阻塞性肺疾病的疗效观察

目的 探讨噻托溴铵联合福莫特罗治疗稳定期慢性阻塞性肺疾病患者的临床疗效.方法 选取我院诊治的130例中重度慢性阻塞性肺疾病患者.采用数字表法随机分为噻托溴铵联合福莫特罗组(A组)和沙美特罗替卡松组(B组),每组各65例,治疗12周后,比较2组的肺功能(第1秒用力肺活量、用力肺活量)和CAT评分.结果 治疗12周后,2组患者FEV1、FVC及CAT评分较治疗前均明显增高,治疗前后比较差异均有统计学意义(P＜0.05).治疗后,A组患者FEV1、FVC高于B组,2组比较差异有统计学意义(P＜0.05).CAT评分2组差异无统计学意义(P＞0.05).结论 治疗12周后,噻托溴铵联合福莫特罗组对中重度COPD患者的肺功能的提高明显优于沙美特罗替卡松.     

Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial

CONTEXT: Inhaled long-acting beta(2)-agonists improve asthma control when added to inhaled corticosteroid (ICS) therapy. OBJECTIVE: To determine whether ICS therapy can be reduced or eliminated in patients with persistent asthma after adding a long-acting beta(2)-agonist to their treatment regimen. DESIGN AND SETTING: A 24-week randomized, controlled, blinded, double-dummy, parallel-group trial conducted at 6 National Institutes of Health-sponsored, university-based ambulatory care centers from February 1997 through January 1999. PARTICIPANTS: One hundred seventy-five patients aged 12 through 65 years with persistent asthma that was suboptimally controlled during a 6-week run-in period of treatment with inhaled triamcinolone acetonide (400 microg twice per day). INTERVENTION: Patients continued triamcinolone therapy and were randomly assigned to receive add-on therapy with either placebo (placebo-minus group, n = 21) or salmeterol xinafoate, 42 microg twice per day (n = 154) for 2 weeks. The entire placebo-minus group was assigned and half of the salmeterol group (salmeterol-minus group) was randomly assigned to reduce by 50% (for 8 weeks) then eliminate (for 8 weeks) triamcinolone treatment. The other half of the salmeterol group (salmeterol-plus group) was randomly assigned to continue both salmeterol and triamcinolone for the remaining 16 weeks (active control group). MAIN OUTCOME MEASURE: Time to asthma treatment failure in patients receiving salmeterol. RESULTS: Treatment failure occurred in 8.3% (95% confidence interval [CI], 2%-15%) of the salmeterol-minus group 8 weeks after triamcinolone treatment was reduced compared with 2.8% (95% CI, 0%-7%) of the salmeterol-plus group during the same period. Treatment failure occurred in 46.3% (95% CI, 34%-59%) of the salmeterol-minus group 8 weeks after triamcinolone therapy was eliminated compared with 13.7% (95% CI, 5%-22%) of the salmeterol-plus group. The relative risk (95% CI) of treatment failure at the end of the triamcinolone elimination phase in the salmeterol-minus group was 4.3 (2.0-9.2) compared with the salmeterol-plus group (P<.001). CONCLUSIONS: Our results indicate that in patients with persistent asthma suboptimally controlled by triamcinolone therapy alone but whose asthma symptoms improve after addition of salmeterol, a substantial reduction (50%) in triamcinolone dose can occur without a significant loss of asthma control. However, total elimination of triamcinolone therapy results in a significant deterioration in asthma control and, therefore, cannot be recommended.     

A cumulative dose comparison between salbutamol and fenoterol metered dose aerosols in asthmatic patients

The potency and side effects of salbutamol and fenoterol inhalers have been compared in 8 asthmatic patients using a dose response curve. There was no significant difference in the absolute or percentage increase in FEV1 with the two treatments, but fenoterol caused a significantly greater (P less than 0.01) increase in heart rate than did salbutamol. A greater degree of bronchodilatation was observed with increased doses and we suggest that regular higher doses may provide better bronchodilatation and control of asthma in selected patients.     

不同装置雾化吸入治疗在婴幼儿急性喘息性疾病中的对比研究

目的比较不同雾化装置吸入治疗在婴幼儿急性喘息性疾病中的效果及影响因素。方法将185例3个月~3岁急性喘息性疾病患儿随机分为压力定量式气雾剂+储雾罐治疗组(P组)、雾化器治疗组(N组)、口服沙丁胺醇治疗组(对照组,C组),雾化吸入药物均为糖皮质激素加短效β2受体激动剂(沙丁胺醇),观察各组的显效率、有效率及P组和N组雾化治疗的依从性和不良反应情况,并使用Logistic回归分析来探讨雾化治疗效果的影响因素。结果 P组和N组显效率均高于对照组;P组和N组雾化治疗效果及依从性无显著性差异,不良反应均较少;哮喘预测指数阳性及雾化治疗依从性高可能是疗效的保护性因素。结论压力定量式气雾剂+储雾罐及雾化器雾化吸入糖皮质激素联合短效β2受体激动剂治疗婴幼儿急性喘息性疾病均安全有效,选择治疗方案时要关注哮喘预测指数及依从性。     

雾化吸入布地奈德对哮喘儿童肺功能的影响

目的：探讨雾化吸入布地奈德福莫特罗粉加沙丁胺醇治疗儿童哮喘急性发作的疗效.方法：2006-01/2007-12我院儿科门诊哮喘患儿130例,随机分为3组：①A组（n=60）,用雾化器吸入布地奈德福莫特罗粉加沙丁胺醇混悬液;②B组（n=45）,使用贮雾罐和面罩,吸入布地奈德福莫特罗粉加沙丁胺醇气雾剂;③对照组（n=25）,不接受表面激素的吸入治疗.观察期为1a,在第4,12,24,48周随访,记录观察期的临床症状评分及哮喘急性发作时药物使用的情况.结果：与对照组相比,A组和B组明显降低了日间症状评分、夜间症状评分,有更多的无症状天数;显著减少了口服激素和吸入速效β2受体激动剂的需求,减少了哮喘的急性发作.而A组在观察期的第4,12周的治疗效果比B组更明显（P〈0.05）,两组在观察期的第24,48周的治疗指标的差异则无统计学意义.结论：雾化吸入布地奈德福莫特罗粉加沙丁胺醇治疗可以更好地减轻哮喘症状,更早地达到长期稳定,是婴幼儿哮喘的首选吸入方式.     

沙美特罗氟替卡松吸入剂与布地奈德吸入剂对慢性中度持续支气管哮喘肺功能影响的对照研究

目的:探讨沙美特罗氟替卡松与布地奈德对慢性中度持续支气管哮喘患者的肺功能的影响。方法:将54例慢性中度持续哮喘患者随机分为对照组、沙美特罗氟替卡松组及布地奈德组,每组18例。对照组患者接受沙丁胺醇吸入,沙美特罗氟替卡松组患者给予沙美特罗氟替卡松吸入,布地奈德组患者给予布地奈德吸入。3个月后比较每组治疗前后肺功能变化及治疗后肺功能改善率。结果:沙美特罗氟替卡松组及布地奈德组治疗前后肺功能有明显改善,差异有统计学意义(P<0.05);对照组治疗前后肺功能无改善,差异无统计学意义(P>0.05);与对照组比较,沙美特罗氟替卡松组及布地奈德组治疗后肺功能改善率差异有统计学意义(P<0.01);与布地奈德组比较,沙美特罗氟替卡松组治疗后肺功能改善率差异有统计学意义(P<0.05)。结论:沙美特罗氟替卡松与布地奈德对慢性中度持续支气管哮喘患者的肺功能均有改善作用,但沙美特罗氟替卡松效果更佳。     

联合吸入糖皮质激素及长效β2-受体激动剂对COPD患者肺功能和气道炎症影响的比较

目的 比较长期联合吸入糖皮质激素（ISC）及长效β2-受体激动剂（LABA）与单药吸入糖皮质激素或长效β2-受体激动剂对改善慢性阻塞性肺疾病（COPD）患者肺功能及气道炎症的作用。方法 将60例中度COPD患者随机分为4组：治疗1组吸入沙莫特罗/氟替卡松,治疗2组吸入福莫特罗,治疗3组吸入布地奈德,对照组按需应用氨荼碱、短效β2受体激动剂。分别在治疗前及治疗后3、6、12、24个月检查动脉血气分析、第1秒用力呼气容量占用力肺活量的百分比（FEV1.0%）、血清肿瘤坏死因子α（TNF-α）和血清转化生长因子-β（TGF-β）。结果 各治疗组患者的急性发作次数均明显减少,与对照组比较差异有统计学意义（P<0.05）,治疗1组效果更为显著（P<0.01）。6个月后各治疗组FEV1.0%、TGF β、TNF-α较对照组改善显著（P<0.05）,治疗1组改善更为显著（P<0.01）;但治疗24个月较12个月未见继续改善（P>0.05）。对照组较治疗前无显著性变化（P>0.05）。4组患者的PaO2 较治疗前差异无统计学意义（P>0.05）。结论 长期联合吸入ISC+LABA、单一吸入ISC或LABA均可以减少COPD患者急性发作次数,改善肺功能,降低血清TGF-β、血清TNF-α的浓度。联合吸入ISC+LABA较单一吸入ISC或LABA效果更显著。     

A comparison between a combination of ipratropium bromide plus fenoterol in a single metered dose inhaler (Duovent) and salbutamol in asthma.

The efficacy of a single metered dose inhaler containing a combination of fenoterol (100 micrograms/puff) and ipratropium bromide (40 micrograms/puff) has been assessed in 12 asthmatics. We conclude that the bronchodilator effect of 2 puffs of the combination inhaler was significantly greater than that achieved by 2 puffs of salbutamol (100 micrograms/puff).